Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Oct. 25, 2016 -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2016 in the lawsuit that was filed for certain investors in shares of American Renal Associates Holdings Inc (NYSE:ARA) over alleged Securities Laws Violations by American Renal Associates Holdings.
The lawsuit seeks to recover damages for certain NYSE:ARA investors.
Investors who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that American Renal Associates Holdings Inc was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for the Company’s dialysis services, that the foregoing scheme was in violation of federal and state laws, and that as a result of the foregoing, American Renal Associates Holdings’ public statements were materially false and misleading at all relevant times.
On August 18, 2016, the Centers for Medicare and Medicaid Services, a federal agency within the U.S. Department of Health and Human Services, announced that it had sent warning letters to all dialysis centers that participate in the federal Medicare program. The Centers for Medicare and Medicaid Services also stated that it is weighing financial penalties on providers found to have directed people eligible for Medicare into Affordable Care Act plans instead—as American Renal is alleged to have done.
Those who purchased American Renal Associates Holdings Inc (NYSE:ARA) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
